Comparative Pharmacology
Head-to-head clinical analysis: KARBINAL ER versus LORATADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KARBINAL ER versus LORATADINE.
KARBINAL ER vs LORATADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbinoxamine is a first-generation antihistamine with anticholinergic and sedative properties. It competitively antagonizes histamine at H1 receptor sites, thereby alleviating symptoms of allergic reactions.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
Adults: 1-2 tablets (6-12 mg carbinoxamine) orally every 4-6 hours as needed; maximum 24 mg/day.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life ranges from 20 to 30 hours, supporting once-daily dosing in extended-release formulation.
Clinical Note
moderateLoratadine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Sulfisoxazole
Loratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Renal (approximately 50% as unchanged drug and metabolites); fecal (approximately 40%); biliary (minor).
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Category C
Category A/B
Antihistamine
Antihistamine
"The metabolism of Sulfisoxazole can be decreased when combined with Loratadine."